Recursion Pharmaceuticals, Inc. Q3 2025 Earnings Recap

RXRX Q3 2025 November 7, 2025

Get alerts when RXRX reports next quarter

Recursion's Q3 2025 earnings report reflects strong operational momentum, highlighted by a significant milestone payment from Roche and a sustained cash balance to support future initiatives under new CEO, Najat Khan.

Earnings Per Share Beat

$-0.36 vs $-0.38 est.

+5.3% surprise

Revenue Miss

5175000 vs 24557140 est.

-78.9% surprise

Market Reaction

1-Day +0.0%

5-Day +0.65%

30-Day -2.91%

See RXRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Transition of leadership with Najat Khan stepping in as CEO on January 1, signaling a bold new strategic focus for the company.
Achieved $30 million milestone payment from Roche, contributing to over $0.5 billion in total cash inflows from partnerships—a notable accomplishment for a pre-commercial biotech firm.
Robust cash position of nearly $800 million, providing operational runway through 2027 without additional financing, enabling the pursuit of multiple upcoming catalysts.
Continued advancements in the neuro map and microglial cell projects, critical for developing novel therapeutics in neuroscience and oncology.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RXRX on AllInvestView.

Next Q1 2026